The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
New therapeutic approaches for metastatic thyroid carcinoma
Abstract
Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DePTC, which accounts for approximately 5-10% of patients with PTC, leads to resistance to traditional therapeutic strategies and worsens prognosis [9, 10, 29].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [29]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Williams Textbook of Endocrinology
Melmed, S., & Polonsky, K. S. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,715
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,379
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,047
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,014
Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970
Self-citationDurante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670
Self-citationTyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402
HAY, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 731
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711
Research works printed but not linked: 1
- Brierley, 2006, Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. American Thyroid Association meeting, Phoenix, October 2006, Thyroid, 16, 857
Cited by
Sorted by citations
Guidelines for radioiodine therapy of differentiated thyroid cancer
Luster, M., Clarke, S. E., Dietlein, M., Laßmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0883-1 · Cited by 725
“Another explanation for the low response rates may be that studies till now have not screened patients for retinoid receptor expression; use of such screening might increase response rates even as it narrows the treated population [ 10 , 100].”
BackgroundInfluentialCarr, L. L., Mankoff, D. A., Goulart, B., Eaton, K. D., Capell, P. T., Kell, E., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 425
Bible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 420
Thyroid carcinoma: molecular pathways and therapeutic targets
Nikiforov, Y. E. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.10 · Cited by 394
“Preliminary results of the trial in patients with progressive papillary carcinoma have shown minimal or partial response in some patients”
ResultMolecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Nikiforova, M. N., & Nikiforov, Y. E. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.1.83 · Cited by 277
Metadata
- Authors
- Baudin, E., & Schlumberger, M.
- Affiliations
- Institut Gustave Roussy (FR)
- ORCID
- Schlumberger, Martin
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 148-156
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2132185197
- Cited by
- 143
- References
- 77
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2020: 6 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 7 · 2012: 8
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- metastatic thyroid cancer, differentiated thyroid cancer, radioiodine therapy, targeted therapy, radioiodine resistance, distant metastasis, treatment options
- MeSH terms
- Humans, Iodine Radioisotopes, Thyroid Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
